The role of pharmacogenomics and tamoxifen was investigated by analyzing several polymorphisms of cytochrome P450 and SULT1A1 gene in a nested case control study from the Italian Tamoxifen Prevention Trial. This study included 182 Caucasian subjects, 47 breast cancer (BC) cases and 135 matched controls. We used the AmpliChip CYP450 Test to screen 33 alleles of CYP2D6 and 3 of CYP2C19. One more variant for CYP2C19*17 and two single-nucleotide polymorphisms for the gene SULT1A1 were also performed. By using the AmpliChip CYP450 Test, out of 182 subjects, we identified 8 poor metabolizer (PM), 17 intermediate metabolizer (IM), 151 extensive metabolizer (EM) and 3 ultrarapid metabolizer (UM). PM women allocated to the tamoxifen arm showed a higher risk of developing BC compared to the remaining phenotypes (P ¼ 0.035). In an exploratory analysis, among 58 women with a CYP2D6*2A allele, 9 BCs were diagnosed in the placebo arm and only 1 in the tamoxifen arm (P ¼ 0.0001). CYP2C19 and SULT1A1 polymorphisms did not show any correlation with tamoxifen efficacy. Tamoxifen showed reduced efficacy in CYP2D6 PMs in the chemoprevention setting. Conversely, the CYP2D6*2A allele may be associated with increased efficacy of tamoxifen. These findings support the relevance of pharmacogenomics in tailoring tamoxifen treatment.
Introduction
Tamoxifen is the most widely used drug for the prevention of hormone-receptorpositive breast cancer (BC), 1 the treatment of ductal carcinoma in situ, 2 the adjuvant treatment of premenopausal BC 3 and the therapy of male BC. 4 Nevertheless, its clinical effectiveness varies among individuals. Cytochrome 450 (CYP450) is the major mediator of drug metabolism. It is a family of several isoenzymes, and each may have different singlenucleotide polymorphisms (SNPs) resulting in the enhancement or reduction of enzyme activity. CYP2D6 and CYP2C19 are involved in the metabolism of several different hormones and drugs, and are among the first examples of genetic polymorphisms identified in the superfamily of CYP enzymes. 5 CYP2D6 catalyzes the bioconversion of approximately 25% of commonly used drugs, such as b-blockers, antiarrhythmic agents, tricyclic antidepressants, selective serotonin-reuptake inhibitors, opioids and anticancer agents, including tamoxifen.
The CYP2C19 enzyme metabolizes more than 25 drugs, including some antidepressants, proton pump inhibitors and tamoxifen. 8 Recently it has been shown that CYP2C19 has a role in the activation of clopidogrel, an antiaggregant drug. SNP variants of this enzyme interfere with the clinical activity of this drug, to the point where the FDA were induced to request a modification in the prescribing information of the drug. 9 More than 70 alleles of CYP2D6 and about 20 alleles of CYP2C19 have been identified with large interindividual and interethnic differences. The resulting CYP2D6 phenotypes can be classified into poor metabolizers (PMs), with two nonfunctional genes; intermediate metabolizers (IMs), including one nonfunctional and one reduced activity, or two alleles with reduced activity; extensive metabolizers (EMs), with at least one normal allele and ultrarapid metabolizers (UMs) due to the presence of more than two functional alleles (http:// www.cypalleles.ki.se). 7, 10, 11 Two main CYP2C19 phenotypes have been described: poor (two nonfunctional genes, namely *2 and/or *3) and EMs (at least one functional allele, namely *1). Recently, a novel allele, CYP2C19*17, has been described: 12 this variant is associated with an increased enzyme activity due to enhanced gene expression. This allele is genetically defined by the two SNPs, CYP2C19-3402 C4T and CYP2C19-806 C4T, that were found to be in complete linkage in the populations studied by Sim et al.
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Tamoxifen is a prodrug undergoing considerable first-pass oxidative metabolism into more potent active metabolites, such as 4-hydroxytamoxifen (4-OH-tamoxifen) and 4-hydroxy-N-desmethyl-tamoxifen (endoxifen). 13, 14 They both have a 30-to 100-fold higher affinity to ER receptors compared to tamoxifen, respectively. Because endoxifen reaches a steady-state plasma concentration 6-to 10-fold higher than 4-OH-tamoxifen, 10, 14, 15 it is considered the most relevant metabolite in determining the parent drug's clinical efficacy. CYP2D6 is one of the most significant enzymes that modulates plasma endoxifen concentration. 14 The relationship of CYP2D6 activity, the level of endoxifen and the antiestrogenic activity has been recently clarified by Wu et al. 16 However, many other enzymes are involved in the pathway, including CYP3A4, CYP2C9, CYP2B6 and CYP2C19 17 and may support the metabolic pathway in case of CYP2D6 PM.
Less data are reported for CYP2C19, only recently a clinical role of this enzyme for tamoxifen activity has been shown. 18, 19 Moreover, the clearance, mediated by sulfotransferase (SULT)1A1 and UDP-glucuronosyltransferase (UGT) 2B15 and UGT1A4, may regulate the metabolite concentration as reported by Nowell et al. 20 So far the main focus of research has been on CYP2D6 PMs, although activity enhancement may also have clinical relevance. Genotypically, PM patients or patients receiving CYP2D6-inhibiting drugs have reduced plasma concentrations of endoxifen. 14, 15, 21 At the clinical level, PM subjects with BC on adjuvant tamoxifen tend to have a higher risk of relapse. 22, 23 This worse clinical outcome has been associated with a decreased prevalence of hot flashes, a putative marker of tamoxifen activity. 22 The findings have indicated that CYP2D6 genotype may be an independent predictor of tamoxifen efficacy in women with early BC. This nested study is based on the Italian Tamoxifen Prevention Trial. Hysterectomized healthy women (N ¼ 5408) were randomly assigned to receive 20 mg tamoxifen per day or placebo. After a median 81.2 month followup, we diagnosed 79 subjects with BC (34 in the tamoxifen arm and 45 in the placebo arm, HR (95% CI) 0.75 (0.48-1.18)). 24 To develop a more tailored and more effective chemoprevention strategy, we have recently published preliminary data on this study, 25 indicating that subjects with the CYP2D6*4/*4 genotype were less likely to benefit from tamoxifen as a chemopreventive agent of BC in the prevention setting. Here we present a more comprehensive analysis of allelic variants of CYP2D6, CYP2C19, in the same cohort, using the AmpliChip CYP450 Test (Roche Diagnostics, Monza, Italy). In addition, we studied the CYP2C19*17 allele and two SNPs of the SULT1A1 gene to further characterize the significance of tamoxifen pharmacogenetics.
Materials and methods

Subjects and samples
The subjects were selected from the Italian Tamoxifen Prevention Trial in which 5408 healthy hysterectomized women aged 35-70 years at average risk for BC were randomly assigned to receive tamoxifen (20 mg daily) or placebo for 5 years. The trial subjects characteristics and main findings have already been published. 26, 27 When this study was planned, 79 women had developed BC and no woman had died of BC. Two unaffected control women were matched by age, center and time on study for each case. The institutional review boards at each participating center approved the case-control study and each subject signed an informed consent.
At the follow-up visit, we asked participants if they would be willing to donate a blood sample for genetic research purposes. Forty-seven BC patients and 135 of the selected matched control agreed to donate blood samples for the study. To increase the statistical power of the study, we broke the individual matching and used all available controls, after verifying, however, that patients and controls had similar characteristics. Clinical characteristics are shown in Table 1 .
DNA preparation
Genomic DNA was extracted from whole blood with the QIAamp DNA Blood Kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions and was adjusted to a concentration of 20 ng ml À1 . The samples were stored at À80 1C. The AmpliChip CYP450 Data Analysis Software derived the genotype, listed the corresponding identified alleles, and provided a prediction of the individual's CYP2D6 enzymatic activity by classifying subjects into four classes: UMs, EMs, IMs, and PMs. UMs and EMs have more than two functional alleles and at least one functional allele, respectively; IMs have one null and one reduced activity allele or two reduced activity alleles; while PMs are characterized by having two nonfunctional CYP2D6 alleles.
CYP2C19 genotyping. CYP2C19*1, CYP2C19*2 and CYP2C19*3 polymorphisms were detected by means of the AmpliChip CYP450 Test (Roche Diagnostics), as described in the previous section. The CYP2C19-3402 C4T polymorphism was evaluated by means of restriction fragment length polymorphism analysis: 100 ng of genomic DNA was used as the template for PCR amplification using the primer pairs 2C19-3402F and 2C19-3402R (5 0 -AATAAAGATGACCTTGATCTGG-3 0 and 5 0 -GTCTCCTGAAGTGTCTGTAC-3 0 , respectively). The assays were performed as previously described.
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CYP2C19-806 C4T SNP was discriminated by means of the 5 0 nuclease polymerase chain reaction assay (TaqMan) carried out by starting with 100 ng DNA in a final volume of 25 ml, as described previously. 28 Data were analyzed by an ABIPRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The CYP2C19*1, *2, *3 and *17 alleles were defined according to the 'Allele nomenclature for cytochrome P450 enzymes' (http:// www.cypalleles.ki.se).
SULT1A1 genotyping. We screened for the SULT1A1*2 variant allele by a hybridization probe-based real-time PCR assay by using a Light Cycler (Roche Molecular Biochemicals, Pleasanton, CA, USA), as described previously. 29 To verify the results, we performed a PCRbased restriction fragment length polymorphism assay as described by others, 20, 33, 34 and subjected the resulting PCR product of 281 bp to cleavage by the restriction endonuclease HaeII (New England BioLabs, Ipswich, MA, USA). In addition, the PCR product was bidirectionally sequenced using Big Dye Terminator version 3.1 Cycle Sequencing kit (Applied Biosystems), according to the manufacturer's instructions, on an ABI Prism 3700 DNA Analyzer (Applied Biosystems). Sequencing reactions were performed with the forward and reverse primers identical to those used in the real-time PCR assay and PCR-based restriction fragment length polymorphism assay.
Statistical analysis
The Fisher's exact test and the Mantel-Haenszel test for trend were used to compare the prevalence of the different alleles in cases versus controls within the placebo group, and in the proportion of PM with BC in the placebo group versus the tamoxifen group. All tests were two-sided. Analyses were carried out with the SAS software (version 8.02, Cary, NC, USA).
Results
Subjects and genotype
Out of the 79 subjects affected by BC, 47 were willing to donate blood for the analysis. From the unaffected controls, 135 subjects agreed to participate. All women were Caucasians, median age was 53 years for both cases and controls. The 47 cases included 37 invasive cancers and 10 cases of intraepithelial neoplasia; 27 cases were in the placebo arm and 20 in the tamoxifen arm. Among the 47 tumors, 63% were estrogen receptor positive, 58% progesterone receptor positive and in 26% of the cases the HER2 was overexpressed. Following are the clinical characteristics of the 182 subjects that contributed to BC risk: 69 women had bilateral oophorectomy, 43 had monolateral and 68 had intact ovaries (two subjects were not known). Fifty-eight subjects used, at a certain point, hormonal replacement therapy (6 only before the trial, 31 only during treatment and 21 always, respectively), whereas 124 had never used hormonal therapy. All these characteristics were balanced between arms (data summarized in Table 1) . Table 2 shows the detailed CYP2D6 genotype and predicted phenotype frequency distribution: 82.9% were EMs, 1.6% were UMs, 9.3% were IMs and 4.3% were PMs, Tamoxifen activity based on genotype characterization whereas three subjects could not be evaluated for poor sample quality. All polymorphisms studied were in HardyWeinberg equilibrium.
Genotype and breast cancer Table 3 shows the distribution of CYP2D6 expected phenotypes between BC cases and controls. Within the placebo arm, there was no significant difference in the distribution of CYP2D6 phenotypes between BC cases and unaffected controls. However, in the tamoxifen arm, a significantly higher frequency of PMs in the cancer cases (15.0%) was observed compared to the controls (1.5%) (P ¼ 0.035). Table 4 shows the distribution of CYP2D6*2A alleles between cases and controls. Although the distribution of CYP2D6*2A carriers was not different between BC cases and controls in the placebo group, there was a significantly higher frequency of *2A carriers in the tamoxifen arm in the unaffected subjects (47.7%) than in the cancer cases (5.0%), (P ¼ 0.0001). This suggests that carriers of a CYP2D6*2A may have higher benefit from tamoxifen therapy compared with other genotypes associated with an EM phenotype.
The CYP2C19 analysis included three alleles detected by the AmpliChip CYP450 Test, *1, *2 and *3. The CYP2C19*17 variant, predicted to have a UM phenotype, was analyzed separately. The genotype frequency was: 42.5% *1*1, 24.3% *1*2, 23.2% *1*17, 3.8% *17*17, 4.4% *2/*17, three samples were undetectable. None of the phenotypes analyzed showed any association with BC or with tamoxifen benefit (Table 5) . Table 6 shows the distribution of SULT1A1 genotypes: 52% *1/*1 (EM), 39.6% *1/*2 (IM) and 8.5% *2/*2 (PM), respectively. Low or absent SULT1A1 activity is predicted to result in an accumulation of tamoxifen metabolites and consequently likely to increase efficacy. However, no differences between SULT1A1 genotypes and the risk of developing BC were detected in our study.
Discussion
Over the last few years, the clinical impact of pharmacogenomics has continued to increase. Tamoxifen has a complex pharmacological pathway and its metabolites have a high variability in serum concentrations from patient to patient. 30 Among the several enzymes involved in the metabolic process, CYP2D6 seems to be the most relevant. It is highly polymorphic, and its variants have been classified into four main phenotypes: PMs, IMs, EMs and UMs. The blood concentrations of tamoxifen's most potent and abundant metabolite, endoxifen, have been shown to correlate significantly with the CYP2D6 phenotype. 21, 29 Furthermore, Goetz et al. 22 reported that patients with impaired CYP2D6 metabolism have nearly a twofold higher risk of BC recurrence when treated with tamoxifen in the adjuvant setting. Moreover, the subjects' phenotype appeared to result from the combination of the genotype and drugs (or nutrients) that may interact with CYP450, in particular antidepressants and CYP2D6, as reported by Goetz et al., 31 with a fourfold increase of BC relapse in PM subjects.
In agreement with Goetz' initial observation, 22 we reported that CYP2D6*4/*4 genotype was associated with Tamoxifen activity based on genotype characterization D Serrano et al reduced tamoxifen efficacy even in the prevention setting. 25 In this study, we have expanded the allele coverage for the CYP2D6 genotyping by including more alleles that may affect tamoxifen metabolism. Furthermore, we included two additional enzymes known to affect tamoxifen metabolism, CYP2C19 and SULT1A1, for a more comprehensive investigation of the resulting phenotype. We found 100% concordance between the real-time TaqMan CYP2D6*4 Allelic Odds ratios (ORs) and 95% confidence intervals (CIs) obtained from exact logistic regression. *P ¼ 0.04 and **P ¼ 0.35 for poor metabolizers versus the remaining groups. ***P ¼ 0.0001 for poor metabolizers versus the remaining groups.
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Discrimination Assay and the AmpliChip CYP450 Test for the CYP2D6*4/*4 genotype. However, with the AmpliChip CYP450 Test, three more PMs (genotypes CYP2D6*3/*4, CYP2D6*3/*5 and CYP2D6*4/*7) could be identified in the placebo arm, as compared to the TaqMan CYP2D6*4 test. In addition, three UMs were also identified in the placebo arm. Our findings confirm that tamoxifen-treated women with PM phenotypes appear to have a higher incidence of BC compared with women with other phenotypes (P ¼ 0.035). Interestingly, our expanded genotyping evaluation showed that having at least one CYP2D6*2A allele was associated with a lower risk of developing BC under tamoxifen treatment (P ¼ 0.0001 in Table 4 ) when compared to other EM CYP2D6 variants. This observation is supported by previous findings indicating that CYP2D6*2A alleles, in particularly the À1584G4C polymorphism, can rule out PM phenotype, 32 and appear to confer increased CYP2D6 activity. 33 This observation needs further confirmation and should be investigated in parallel with the endoxifen level associated with this particular genotype.
Although aromatase inhibitors have become the standard adjuvant treatment for postmenopausal positive-estrogenreceptor BC in Europe and North America, 34 tamoxifen is still widely used in premenopause, and at any age in Asia and developing countries. Aromatase inhibitors are not exempt from important adverse events, including musculoskeletal disorders and increased bone fracture risk. Moreover, a provocative computer modeling study suggested that tamoxifen could actually be more effective than aromatase inhibitors if administered only to EM subjects. 35 Genotype information allows physicians to tailor treatment according to the patient's genetic and metabolic profile. This aspect is especially relevant with a narrow therapeutic window. Warfarin is an example: including the genotype information helps to adjust the drug dose. 36 In the adjuvant setting it has been proposed to increase the dose up to 40 mg of tamoxifen in PM subjects. With this dose it has been shown that it is possible to reach similar level of endoxifen in IM and PM phenotype comparing EM with standard dose. 37 In the prevention setting, it is reasonable not to use tamoxifen in PM women, avoiding a potential toxic therapy with little or no benefit at all. Conversely, in UM or even EM, the tamoxifen dose may be personalized to a lower range, for example, 5-10 mg per day, because we showed that low-dose tamoxifen maintains antiproliferative activity on BC whereas toxicity may be reduced. [38] [39] [40] CYP2D6 genotyping could be evaluated together with serum endoxifen levels and biomarkers of tamoxifen activity and safety (for example, mammographic density, IGF-I, SHBG, lipids and endometrial thickness) after a short period of treatment. Such interaction may be a key point to personalized treatment and dose, in a manner that is similar to monitoring statin therapy with cholesterol levels and biphosphonates with bone density. Preliminary data suggest Our study has some limitations. First of all, the retrospective nature of the design is a weakness shared with all other available studies. The small sample size and low PM number gives a low statistical power and does not allow one to study the interactions between other hormonal variants, such as hormone replacement therapy use or oophorectomy, and genotype, that may influence BC risk; the distribution of these variables is, however, balanced between cases and controls in this study sample. Antidepressants, in particular paroxetine and fluoxetine, known to be potent CYP2D6 inhibitors, are commonly prescribed with tamoxifen in the treatment of hot flashes or depression. 15 However, in Italy, antidepressants are not commonly prescribed for management of hot flashes, and our data show that the overall prevalence of these drugs in the trial was below 1% (data on file). Nevertheless, the effect of CYP2D6 inhibitors on the clinical outcomes cannot specifically be addressed in this study.
Many other enzymes are involved in tamoxifen metabolism and the redundancy may mask or balance if one is not functional. Recently, it has been shown that CYP2C19 may be a risk factor per se, or that it can be important for tamoxifen response and is further enhanced by its association with CYP2D6. 19 Our data do not confirm this observation, possibly because of the relatively low number of subjects with these SNPs variants. It has also been reported that SULT1A1 may influence tamoxifen metabolites' concentration. 29, 42, 43 However, previous studies 15, 29 have not shown significant associations between SULT1A1 genotypes and the serum levels of 4OH-tamoxifen or endoxifen per se. Our results did not show any differences between SULT1A1 genotype and BC risk, suggesting that SULT1A1 may not be important in explaining tamoxifen preventive efficacy. A challenge in interpreting the existing literature on CYP2D6 and tamoxifen is that the classifications used to identify different CYP2D6 phenotypes have differed between studies and the allele coverage has been very limited. In this rapidly evolving field, it is very difficult to nail down a definitive classification, because many SNPs and many enzymes concur to the final effect. Furthermore, the redundancy of enzymes in the tamoxifen pathway may reduce the effect of a single enzyme. Some doubts have been raised, lately, on the final clinical relevance of CYP2D6 and tamoxifen activity. 44 The use of an automatic system such as the AmpliChip CYP450 may help to speedup the analytical process with minor limitations in specificity, such as misinterpretation between two SNPs, one EM and the other IM. The goal of pharmacogenomics is to identify biomarkers to be applied in the clinical setting and to implement the new paradigm of tailored medicine. Our findings support the notion that CYP2D6 genotype can be an appropriate fingerprint to design truly tailored treatment with tamoxifen. A well-designed clinical trial is required to unequivocally validate such an approach.
